

Joyce M Slingerland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7893186/publications.pdf>

Version: 2024-02-01

47
papers

8,713
citations

94433

37
h-index

197818

49
g-index

49
all docs

49
docs citations

49
times ranked

14470
citing authors

#	ARTICLE	IF	CITATIONS
1	DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1948-1965.	7.0	21
2	Vitamin C sensitizes triple negative breast cancer to PI3K inhibition therapy. <i>Theranostics</i> , 2021, 11, 3552-3564.	10.0	5
3	Development of a multigenerational digital lifestyle intervention for women cancer survivors and their families. <i>Psycho-Oncology</i> , 2020, 29, 182-194.	2.3	9
4	The Major Pre- and Postmenopausal Estrogens Play Opposing Roles in Obesity-Driven Mammary Inflammation and Breast Cancer Development. <i>Cell Metabolism</i> , 2020, 31, 1154-1172.e9.	16.2	58
5	p27 as a Transcriptional Regulator: New Roles in Development and Cancer. <i>Cancer Research</i> , 2020, 80, 3451-3458.	0.9	75
6	Obtaining Human Breast Adipose Cells for Breast Cancer Cell Co-culture Studies. <i>STAR Protocols</i> , 2020, 1, 100197.	1.2	8
7	p27 transcriptionally coregulates cjun to drive programs of tumor progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 7005-7014.	7.1	29
8	Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer. <i>EBioMedicine</i> , 2019, 43, 201-210.	6.1	19
9	Vitamin C promotes apoptosis in breast cancer cells by increasing TRAIL expression. <i>Scientific Reports</i> , 2018, 8, 5306.	3.3	63
10	Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells. <i>Clinical Cancer Research</i> , 2018, 24, 4874-4886.	7.0	60
11	p16 loss rescues functional decline of Brca1-deficient mammary stem cells. <i>Cell Cycle</i> , 2017, 16, 759-764.	2.6	7
12	<scp>VEGFA</scp> activates an epigenetic pathway upregulating ovarian cancer-initiating cells. <i>EMBO Molecular Medicine</i> , 2017, 9, 304-318.	6.9	63
13	Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 378-397.	329.8	551
14	Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b-Mediated Malignant Progression. <i>Cancer Research</i> , 2016, 76, 491-504.	0.9	142
15	MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 935-947.	7.0	42
16	<i>p16INK4a</i> suppresses BRCA1-deficient mammary tumorigenesis. <i>Oncotarget</i> , 2016, 7, 84496-84507.	1.8	10
17	Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 503-517.	2.5	31
18	Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. <i>Nature Reviews Cancer</i> , 2014, 14, 26-38.	28.4	123

#	ARTICLE	IF	CITATIONS
19	Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways. <i>Cell</i> , 2014, 159, 499-513.	28.9	659
20	Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in β -secretase inhibitor drug responses. <i>EMBO Molecular Medicine</i> , 2013, 5, 1502-1522.	6.9	62
21	Cytokines, Obesity, and Cancer: New Insights on Mechanisms Linking Obesity to Cancer Risk and Progression. <i>Annual Review of Medicine</i> , 2013, 64, 45-57.	12.2	249
22	New insights on the role of hormonal therapy in ovarian cancer. <i>Steroids</i> , 2013, 78, 530-537.	1.8	50
23	PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 369-381.	2.5	46
24	Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models <i>In Vitro</i> and <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2012, 18, 5911-5923.	7.0	69
25	Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer. <i>Endocrine-Related Cancer</i> , 2011, 18, 207-19.	3.1	41
26	Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 69-78.	2.5	48
27	p27: A Barometer of Signaling Deregulation and Potential Predictor of Response to Targeted Therapies. <i>Clinical Cancer Research</i> , 2011, 17, 12-18.	7.0	172
28	Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. <i>Journal of Clinical Investigation</i> , 2011, 121, 1231-1241.	8.2	362
29	Lapatinib: new opportunities for management of breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2010, 2, 79.	1.8	9
30	p27 as Jekyll and Hyde: Regulation of cell cycle and cell motility. <i>Cell Cycle</i> , 2009, 8, 3455-3461.	2.6	107
31	RSK1 drives p27 ^{Kip1} phosphorylation at T198 to promote RhoA inhibition and increase cell motility. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 9268-9273.	7.1	142
32	Combined Src and Aromatase Inhibition Impairs Human Breast Cancer Growth <i>In vivo</i> and Bypass Pathways Are Activated in AZD0530-Resistant Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 3396-3405.	7.0	60
33	The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. <i>Nature Reviews Cancer</i> , 2008, 8, 253-267.	28.4	869
34	mTOR-Raptor Binds and Activates SGK1 to Regulate p27 Phosphorylation. <i>Molecular Cell</i> , 2008, 30, 701-711.	9.7	236
35	Phosphorylation of p27 ^{Kip1} Regulates Assembly and Activation of Cyclin D1-Cdk4. <i>Molecular and Cellular Biology</i> , 2008, 28, 6462-6472.	2.3	94
36	p27 Phosphorylation by Src Regulates Inhibition of Cyclin E-Cdk2. <i>Cell</i> , 2007, 128, 281-294.	28.9	338

#	ARTICLE	IF	CITATIONS
37	The energy sensing LKB1-AMPK pathway regulates p27kip1 phosphorylation mediating the decision to enter autophagy or apoptosis. <i>Nature Cell Biology</i> , 2007, 9, 218-224.	10.3	782
38	Src promotes estrogen-dependent estrogen receptor β proteolysis in human breast cancer. <i>Journal of Clinical Investigation</i> , 2007, 117, 2205-2215.	8.2	76
39	The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. <i>Cancer Research</i> , 2005, 65, 18-25.	0.9	149
40	CRM1/Ran-Mediated Nuclear Export of p27Kip1 Involves a Nuclear Export Signal and Links p27 Export and Proteolysis. <i>Molecular Biology of the Cell</i> , 2003, 14, 201-213.	2.1	174
41	Altered p27 Kip1 Phosphorylation, Localization, and Function in Human Epithelial Cells Resistant to Transforming Growth Factor β -Mediated G1 Arrest. <i>Molecular and Cellular Biology</i> , 2002, 22, 2993-3002.	2.3	64
42	PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. <i>Nature Medicine</i> , 2002, 8, 1153-1160.	30.7	880
43	Constitutive MEK/MAPK Activation Leads to p27Kip1 Deregulation and Antiestrogen Resistance in Human Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2001, 276, 40888-40895.	3.4	116
44	Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. <i>Oncogene</i> , 1999, 18, 1023-1032.	5.9	71
45	E-Cadherin-dependent Growth Suppression is Mediated by the Cyclin-dependent Kinase Inhibitor p27KIP1. <i>Journal of Cell Biology</i> , 1998, 142, 557-571.	5.2	408
46	Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer. <i>Nature Medicine</i> , 1997, 3, 227-230.	30.7	770
47	Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. <i>Nature Medicine</i> , 1996, 2, 1204-1210.	30.7	291